HOME   Cart(0)   Quotation   About-Us Tax PDFs Standard-List Powered by Google www.ChineseStandard.net Database: 189760 (9 Nov 2024)

YY/T 1163-2009 English PDF

YY/T 1163-2009 (YY/T1163-2009, YYT 1163-2009, YYT1163-2009)
Standard IDContents [version]USDSTEP2[PDF] delivered inStandard Title (Description)StatusPDF
YY/T 1163-2009English140 Add to Cart 0--9 seconds. Auto-delivery Total Prostate Specific Antigen (t-PSA) Quantitative Detection Reagent (Kit) (Chemiluminescent Immunoassay) Valid YY/T 1163-2009
Preview PDF: YY/T 1163-2009

BASIC DATA
Standard ID YY/T 1163-2009 (YY/T1163-2009)
Description (Translated English) Total Prostate Specific Antigen (t-PSA) Quantitative Detection Reagent (Kit) (Chemiluminescent Immunoassay)
Sector / Industry Medical Device & Pharmaceutical Industry Standard (Recommended)
Classification of Chinese Standard C44
Classification of International Standard 11.100
Word Count Estimation 10,151
Date of Issue 2009-12-30
Date of Implementation 2011-06-01
Quoted Standard GB/T 21415-2008
Drafting Organization Beijing Medical Device Testing
Administrative Organization National Standardization Technical Committee of Medical clinical testing laboratories and in vitro diagnostic systems
Regulation (derived from) China Food & Drug Administration Announcement 2009 No.83
Summary This standard specifies the total prostate specific antigen (t-PSA) quantitative assay reagent (box) (chemiluminescent immunoassay) products, terms and definitions, classification, requirements, test methods, inspection rules, marking, labeling, instructions, packaging, transport and storage. This standard applies to the principle of chemiluminescence immunoassay for the quantitative detection of human blood or other body fluid composition matrix of total prostate specific antigen (t-PSA) quantitative assay kit (hereinafter referred to as "t-PSA kit"). Including microplates, tubes, magnetic particles, beads and plastic beads, etc. as the carrier of enzymatic and non-enzymatic chemiluminescence immunoassay reagent (box). This standard does not apply to the kit calibrators and control materials requirements.


YY/T 1163-2009 YY ICS 11.100 C 44 Pharmaceutical Industry Standard of the People’s Republic of China Total Prostate Specific Antigen (t-PSA) Quantitative Detection Reagent (Kit) (Chemiluminescent Immunoassay) ISSUED ON. DECEMBER 30, 2009 IMPLEMENTED ON. JUNE 1, 2011 Issued by. State Food and Drug Administration Table of Contents Foreword ... 3  1 Scope ... 4  2 Normative references ... 4  3 Terms and definitions ... 4  4 Classification ... 6  5 Requirements ... 6  6 Test methods ... 8  7 Product inspection rules ... 10  8 Marking, labeling, and instructions ... 12  9 Packaging, transportation, and storage ... 13  References ... 14  Foreword The preparation of this Standard follows the basic specifications of GB/T 1.1-2000 Directives for Standardization. Part 1. Standard Structure and Compilation Rules. It is the basis for evaluating the product quality of total prostate specific antigen (t-PSA) quantitative detection reagent (kit) (chemiluminescent immunoassay). This Standard was proposed by the State Food and Drug Administration. This Standard shall be under the jurisdiction of the National Medical Clinical Testing Laboratory and In Vitro Diagnostic System Standardization Technical Committee (SAC/TC 136). Drafting organizations of this Standard. Beijing Institute of Medical Device Testing, Beijing Yuande Medical Engineering Co., Ltd., Beijing Chemclin Biotech Co., Ltd., Roche Diagnostic Products (Shanghai) Co., Ltd., and Shanghai Abbott Laboratories Co., Ltd. Main drafters of this Standard. Zhang Xinmei, Sun Xudong, Cheng Yinghao, Yang Xiaolin, Cai Xiaorong, and Wang Xuefeng. Prostate Specific Antigen (t-PSA) Quantitative Detection Reagent (Kit) (Chemiluminescent Immunoassay) 1 Scope  This Standard specifies the terms and definitions, classification, requirements, test methods, inspection rules, marks, labels, operating instructions, packaging, transportation, and storage of total prostate specific antigen (t-PSA) quantitative detection reagent (kit) (chemiluminescent immunoassay). This Standard applies to the quantitative detection of total prostate specific antigen (t-PSA) quantitative detection reagent (kit) (herein after referred to as “t-PSA reagent (kit)”) of the human blood matrix or other body fluid components based on the principle of chemiluminescent immunoassay. It includes the enzymatic and non-enzymatic chemiluminescence immunoassay detection reagent (kit) with carriers such as microplates, tubes, magnetic particles, microbeads, and plastic beads. This Standard does not apply to the requirements of the calibrator and quality control material in reagent kits. 2 Normative references  The provisions in following documents become the provisions of this Standard through reference in this Standard. For dated references, the subsequent amendments (excluding corrections) or revisions do not apply to this Standard, however, parties who reach an agreement based on this Standard are encouraged to study if the latest versions of these documents are applicable. For undated references, the latest edition of the referenced document applies. GB/T 21415-2008 In vitro diagnostic medical devices - Measurement of quantities in biological samples - Metrological traceability of values assigned to calibrator and control materials (ISO 17511.2003, IDT) 3 Terms and definitions  The following terms and definitions apply to this Standard. 3.1 Chemiluminescence, CL C0 — Detection concentration of serum sample B; Cs — Concentration of solution A. 6.4 Minimum detection limit USE zero-concentration calibrator or sample diluent as the sample to perform the detection. REPEAT measurement for 20 times. OBTAIN the RLU value (relative luminescence value) of the 20 measurement results. CALCULATE the mean (M) and standard deviation (SD). OBTAIN the M+2SD. CONDUCT two-points regression fitting, based on the concentration – RLU value result BETWEEN zero-concentration calibrator AND adjacent calibrator, to obtain the linear formula. SUBSTITUTE the RLU value of M+2SD into the above formula. OBTAIN the corresponding concentration value, that is, the minimum detection limit. The result shall comply with the requirements of 5.4. 6.5 Linearity DILUTE the samples with high-value close to the upper limit of linear range INTO at least 5 concentrations according to certain proportion. In which, the samples with low-value concentration shall be close to the lower limit of the linear range. OPERATE according to the instructions of reagent (kit). For each concentration, repeatedly DETECT for 2 times. CALCULATE the mean. USE the least square method to perform the straight-line fitting FOR result’s mean and dilution proportion. And CALCULATE the linear correlation coefficient r. The result shall comply with the requirements of 5.5. 6.6 Repeatability USE samples of 4ng/ML ± 0.8ng/mL and 30ng/mL ± 6ng/mL to repeatedly detect for 10 times. CALCULATE the mean M and standard deviation SD of 10-time measured results. CALCULATE coefficient of variation CV according to the formula CV = SD/M × 100%. The results shall comply with the requirements of 5.6. 6.7 Between-batch difference USE 3 batches of reagent kits to detect one sample with concentration of (30±6) ng/mL respectively. REPEAT for 10 times. CALCULATE the mean M and standard deviation SD of 30-time measured results. CALCULATE coefficient of variation CV according to the formula CV = SD/M × 100%. The results shall comply with the requirements of 5.7. 6.8 Stability a) Stability within the period of validity. TAKE the expired sample to inspect according to the methods of 6.3, 6.4, 6.5, and 6.6. It shall comply with the requirements of 5.8 a). 7.4.1 Amount of sampling The amount of sampling of factory-exit inspection shall be three times of the amount of inspection items, including the amount of inspection, amount of re-inspection and the amount of sample. 7.4.2 Inspection items The items of factory-exit inspection shall be clarified. 7.4.3 Conformance determination During the process of inspection, if there is 1 item unqualified, then it shall conduct re-inspection. If there is 1 item unqualified in the re-inspection, then this batch of reagent (kit) is deemed as unqualified. 7.4.4 The retained sample reagent (kit) is used for re-inspection in special cases, such as quality complaints from users. If it is not used in re-inspection, then the reagent (kit) shall be destroyed in two months after the period of validity. 7.5 Type inspection 7.5.1 When there is one of the following conditions, it shall conduct type inspection. a) Launch of new products; b) When there is significant changes to the material, formula and process; c) Not less than once a year in continuous production; d) When production is resumed after the long-term shutdown; e) When it is required by the contract provisions or the administrative department. 7.5.2 Amount of sampling The amount of sampling of type inspection shall be three times of the amount of inspection items, including the amount of inspection, amount of re-inspection and the amount of sample. 7.5.3 Inspection items When conducting type inspection, it shall conduct full-inspection. All inspection results shall be qualified. 7.5.4 Conformance determination If all inspection items are qualified, the type inspection is passed. If the type inspection References [1] GB/T 191 Packaging - Pictorial marking for handling of goods [2] GB/T 9969 General principles for preparation of instructions for use of industrial products [3] YY 0466 Medical devices - Symbols to be used with medical device labels labeling and information to be supplied (ISO 15223-2000, IDT) [4] GB/T 19702-2005 In vitro diagnostic medical devices - Measurement of quantities in samples of biological origin - Requirements for content and presentation of reference measurement procedures (ISO 15193.2002, IDT) [5] ISO/DIS 18113-1 Clinical laboratory testing and in vitro diagnostic medical systems - Information supplied by the manufacturer (labeling) - Part 1. Terms, definitions and general requirements ......